Levy et al. 2015, demonstrated that expression of the LIF receptors was strongly increased on immune cells of RRMS patients, whereas, the secreted LIF levels from immune cells of RRMS patients were downregulated compared to healthy controls. This evidence concerns the gene LIFR and relapsing-remitting multiple sclerosis.